Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed

Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
168 Clinical Updates found
MSK researchers presented advances in new treatment approaches for several cancer indications at the 2023 ASCO annual meeting.
MSK Research Roundup at ASCO 2023: Advances in Glioma, Rectal Cancer, Lung Cancer, Biliary Tract Cancer, and More

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough advances in new treatment approaches for several cancer indications at the 2023 ASCO Annual Meeting held June 2 to 6, 2023. Highlights of practice-changing study results in glioma, rectal cancer, non-small cell lung cancer, biliary tract cancer, and more were as follows:
Case Study: MSK’s Approach to Complex Pediatric Surgical Oncology
Case Study: MSK’s Approach to Complex Pediatric Surgical Oncology

The American College of Surgeons recently designated Memorial Sloan Kettering Cancer Center (MSK) the first-ever Children’s Surgery Verification (CSV) Quality Improvement Program Level I Specialty Children’s Surgery Center in Oncology. The distinction recognizes MSK as a highly specialized hospital providing exceptional surgical care that matches children’s needs with optimal pediatric resources.
The Enid A. Haupt Chair in Surgery, Michael D’Angelica, MD, FACS, and Ryan Ellis, MD, MS, Chief Surgery Fellow co-authored a study that supports using piperacillin-tazobactam as a standard of care for patients undergoing open pancreatoduodenectomy.
Broad-Spectrum Antibiotic Significantly Reduces Surgical Site Infections After the Whipple Procedure

The broad-spectrum antibiotic piperacillin-tazobactam used as perioperative prophylaxis significantly reduced surgical site infection (SSI) in patients undergoing open pancreatoduodenectomy (PD, or the Whipple procedure) compared with the standard-of-care cefoxitin, according to results from the first-ever registry-linked surgical clinical trial conducted in North America. The findings, published in JAMA on April 20, support using piperacillin-tazobactam as a standard of care for this patient population.
Laboratory equipment for researchers
MSK Research Roundup at AACR 2023: Exciting Advances in Clinical, Translational, and Foundational Research

Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest clinical, translational, and foundational cancer research at ...
MSK Researchers Discover Targetable Mechanism Driving Late Cardiac Toxicity After DNA-Damaging Cancer Treatment
MSK Researchers Discover Targetable Mechanism Driving Late Cardiac Toxicity After DNA-Damaging Cancer Treatment

Memorial Sloan Kettering Cancer Center (MSK) researchers have discovered that innate immune signaling drives late cardiac toxicity after DNA-damaging c...
Medical Oncologist Mrinal Gounder, MD
Nirogacestat Improves Outcomes for Patients With Desmoid Tumors

The targeted therapy nirogacestat demonstrated rapid and sustained improvements for adults with progressing desmoid tumors, according to results from a...
physician-scientist Sarat Chandarlapaty, MD, PhD and colleague working in their MSK laboratory.
A Decade of MSK Research Laid Groundwork for Recent Approval of a Targeted Therapy for Metastatic Breast Cancer

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.
CAR T cell therapy
Allogeneic CAR T Cell Therapy for Multiple Myeloma Shows Promise

A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial (NCT04093596) published recently in Nature Medicine.
Photo of person walking in front of MSK Kids sign
Top Pediatric Cancer Advances at MSK Kids in 2022

Doctors at MSK Kids, the dedicated pediatric service at Memorial Sloan Kettering Cancer Center (MSK), pioneered many advances for pediatric patients in 2022.
Spine Neurosurgeon and Director of Minimally Invasive Spine Oncology at MSK, Ori Barzilai, MD, reviews imaging.
Advancing Spinal Metastasis Care Through Genomic Insights

Building on a legacy of pioneering and validating advances in spinal metastasis care, neurosurgeons and radiation oncologists with the Memorial Sloan Kettering Cancer Center (MSK) Multidisciplinary Spine Tumor Service have been investigating the clinical utility of genomic data as the next frontier for improving patient outcomes.